Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Gamma-aminobutyric acid-gated chloride channel subunit RDL (RDL) is a critical component of the inhibitory neurotransmitter system in the central nervous system of arthropods, including ticks and various insect pests (Ffrench-Constant, 1993). As a member of the Cys-loop ligand-gated ion channel superfamily, it forms homomeric or heteromeric pentameric channels that mediate fast inhibitory synaptic transmission by conducting chloride ions upon GABA binding (Casida & Durkin, 2013). This target is of immense pharmacological importance as it is the site of action for major classes of insecticides and acaricides, such as phenylpyrazoles (e.g., fipronil) and the newer isoxazoline class (e.g., fluralaner, afoxolaner) (Gassel et al., 2014). These drugs function as non-competitive antagonists, binding to an allosteric site within the channel's transmembrane pore to block chloride flow. This blockage leads to neuronal hyperexcitation, paralysis, and death of the parasite (Weber & Selzer, 2016). The therapeutic utility of targeting RDL stems from its high selectivity; structural differences between the invertebrate RDL receptor and the mammalian GABA-A receptor allow these drugs to be highly toxic to parasites while remaining safe for the host (Ozoe, 2013). Resistance to these agents is frequently associated with specific point mutations in the RDL gene, such as the A301S or A301G substitutions, which reduce drug binding affinity (Ffrench-Constant et al., 2000). Consequently, monitoring these mutations is essential for managing resistance in veterinary and agricultural settings.
Non-competitive antagonism of the chloride channel pore, leading to hyperexcitation and paralysis of the parasite.
8 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Gamma-aminobutyric acid-gated chloride channel subunit RDL (RDL) (RDL).